See how IPA can help you: Start a free trial of IPA
This independent white paper by Life Science Insights (an IDC company), discusses the significant ROI that pathway analysis tools bring to the drug discovery and development cycle.
Based on in-depth interviews with researchers and senior managers at pharmaceutical companies, this study concludes that there is a significant return on investment (ROI) from the use of IPA® within the context of traditional drug discovery and development. The research on IPA showed that companies can reap a significant ROI based on improvements in productivity, cost savings, and innovation across all phases of the drug development process from discovery through marketing, including:
"IPA helps us understand the gene expression data and why exposure to a particular drug causes gene expression events. These gene expression events can be used as biomarkers in our animal experiments. Next, using IPA, we can determine if the biomarker is found in blood, synovial fluid, or a skin biopsy, and then we can take the data to the clinic and eventually use the biomarker during human trials."
Biomarker development and validation group leader
"We were working on a data set for over a year trying to prioritize the targets, but we had no good way to analyze it. We ran it through IPA and immediately identified the pathways. If we would have had that information a year ago, it would have saved us considerable time and provided the right place to start."
Scientist, investigative pathology
"It definitely helps you strengthen and define your next round of studies. IPA helps you validate or ’disvalidate’ your hypothesis."
Principal research scientist, genomics department
Based on in-depth interviews with researchers and senior managers at pharmaceutical companies, this study concludes that there is a significant return on investment (ROI) from the use of IPA® within the context of traditional drug discovery and development. The research on IPA showed that companies can reap a significant ROI based on improvements in productivity, cost savings, and innovation across all phases of the drug development process from discovery through marketing, including:
- Target ID, qualification, and prioritization
- Target validation
- Lead optimization
- Preclinical studies
- Clinical studies/patient stratification
- FDA submission and approval
"IPA helps us understand the gene expression data and why exposure to a particular drug causes gene expression events. These gene expression events can be used as biomarkers in our animal experiments. Next, using IPA, we can determine if the biomarker is found in blood, synovial fluid, or a skin biopsy, and then we can take the data to the clinic and eventually use the biomarker during human trials."
Biomarker development and validation group leader
"We were working on a data set for over a year trying to prioritize the targets, but we had no good way to analyze it. We ran it through IPA and immediately identified the pathways. If we would have had that information a year ago, it would have saved us considerable time and provided the right place to start."
Scientist, investigative pathology
"It definitely helps you strengthen and define your next round of studies. IPA helps you validate or ’disvalidate’ your hypothesis."
Principal research scientist, genomics department
The Return on Investment for IPA within the Pharmaceutical Value Chain
Learn more about IPA on our website, www.ingenuity.com
Click here to register for a free, fully functional trial of IPA.
Click here to register for a free, fully functional trial of IPA.